On September 9, 2026 1cBio, a biopharmaceutical company focused on discovering and developing innovative therapies for serious and underserved conditions including oncology and metabolic diseases, and Lee’s Pharmaceutical Holdings Ltd. ("Lee’s Pharm"), reported that the companies have entered into a licensing agreement granting Lee’s Pharm exclusive rights to develop and commercialize 1cBio’s lead PARP1 inhibitor, OC-3, in China and certain countries in Southeast Asia. Under the terms of the agreement, 1cBio is eligible to receive an upfront payment, development milestones and potential sales milestone payments totaling up to US$27 million, as well as royalties on future net sales.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OC-3, currently in preclinical development, is a potential best-in-class PARP1 inhibitor for the treatment of cancers that are defective in DNA homologous recombination repair. These cancer types include predominately prostate, ovarian, breast and pancreatic cancers with known mutations in DNA repair genes such as BRCA1, BRCA2 or PALB2. In preclinical models of cancers known to have DNA repair deficiency of this kind, OC-3 demonstrated potent anticancer activities.
"This agreement with Lee’s Pharm provides 1cBio a valued China-based drug development and commercialization partner for OC-3," said Andrew Protter, PhD, CEO of 1cBio. "With Lee’s Pharm, 1cBio collaborates with a team that has a robust oncology group, strong manufacturing capabilities, and a proven ability to advance assets in various stages of development in Asia. This partnership will provide valuable resources as we work toward filing an IND in the U.S. and advancing OC-3 into clinical trials for patients with solid tumors."
"We believe that OC-3’s PARP1 inhibitor has the potential to become an important new treatment option for patients with cancer, with a differentiated profile that may offer meaningful improvements in both safety and efficacy," said Benjamin Li, Founder and Director of Lee’s Pharm. "We are pleased to enter into this collaborative development agreement with 1cBio and look forward to working together to advance the program."
Lee’s Pharm will be responsible for Good Laboratory Practice (GLP) safety studies and manufacturing activities required to gain regulatory approval for OC-3 in China and the other Southeast Asian territories included in the license. A drug supply manufacturing agreement is also included.
As part of the agreement, 1cBio will have rights to access and use any data generated as part of its efforts to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
(Press release, 1cBio, SEP 9, 2026, View Source [SID1234670685])